Breast Cancer

CHICAGO — Trastuzumab deruxtecan significantly extended PFS and OS among patients with HER2-low metastatic breast cancer, regardless of hormone receptor status, compared with standard of care therapy.

CHICAGO — During the ASCO Annual Meeting, Healio honored our inaugural Healio Disruptive Innovators in hematology/oncology.

CHICAGO — The keynote speaker at ASCO Annual Meeting urged attendees to focus on social and organizational innovations that can advance equity in cancer care.

CHICAGO — Sacituzumab govitecan significantly extended PFS vs. single-agent chemotherapy among patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer, according to study results.

The percentage of patients presenting with late-stage breast and colorectal cancers increased between 2019 and 2020 at Moores Cancer Center at University of California San Diego Health, according to data published in JAMA Network Open.

Women demonstrated a 34% increased risk for severe adverse events from any cancer treatment compared with men, according to a study published in Journal of Clinical Oncology.

Healio and Cardiology Today have compiled a list of the most-read news in cardiology of May 2022.

Stephanie L. Graff, MD, FACP, spoke with Healio about the breast cancer-focused sessions she is most excited to attend at the ASCO Annual Meeting, taking place June 3-7 in Chicago.

The addition of bevacizumab to chemotherapy did not appear to be negatively associated with quality of life at 18 months in lymph node-positive or high-risk lymph node-negative breast cancer, according to a study in JAMA Network Open.

Most Black patients with cancer reported a somewhat or very high likelihood of considering clinical trial participation, yet many had not been informed of the opportunity to enroll onto a clinical trial, study results showed.